nystatin-a1 and Candidiasis--Cutaneous

Cutaneous candidiasis is a common skin disease, and several treatments have been investigated within the last fifty years. Yet, systematic reviews are lacking, and evidence-based topical and systemic treatment strategies remain unclear. Thus, the aim of this review was to summarize efficacy and adverse effects of topical and oral therapies for cutaneous candidiasis in all age groups. Two individual researchers searched PubMed and EMBASE for 'cutaneous candidiasis' and 'cutaneous candidiasis treatment', 'intertrigo', 'diaper dermatitis' and 'cheilitis'. Searches were limited to 'English language', 'clinical trials' and 'human subjects', and prospective clinical trials published in abstracts or articles were included. In total, 149 studies were identified, of which 44 were eligible, comprising 41 studies of 19 topical therapies and four studies of three systemic therapies for cutaneous candidiasis. Topical therapies were investigated in infants, children, adolescents, adults and elderly, while studies of systemic therapies were limited to adolescents and adults. Clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated similar efficacy with complete cure rates of 73%-100%. Single-drug therapy was as effective as combinations of antifungal, antibacterial and topical corticosteroid. Four studies investigated systemic therapy, and oral fluconazole demonstrated similar efficacy to oral ketoconazole and topical clotrimazole. Limitations to this review were mainly that heterogeneity of studies hindered meta-analyses. In conclusions, clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated equal good efficacy and mild adverse effects similar to combinations of antifungal, antibacterial and topical corticosteroids. Oral fluconazole was as effective as topical clotrimazole and is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.

Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candidiasis, Cutaneous; Clotrimazole; Drug Therapy, Combination; Evidence-Based Medicine; Fluconazole; Humans; Ketoconazole; Miconazole; Nystatin

We describe congenital cutaneous candidiasis (CCC) in a term newborn. The mother had candidal vaginitis 1 week before delivery. At birth, the infant had a generalized, intensely erythematous, papulovesicular eruption, respiratory distress and elevation of liver function tests. The child responded well to intravenous amphotericin B plus topical and oral nystatin. There have been 13 previously reported cases of CCC in infants weighing more than 1500 gm who had evidence of systemic infection. Two deaths were attributed to candidal pneumonia and sepsis. The majority of infants with CCC have infection localized to the skin, but if there is any evidence of respiratory distress or signs of sepsis the possibility of systemic candidiasis and the need for parenteral antifungal therapy must be considered.

Topics: Amphotericin B; Antifungal Agents; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Liver Function Tests; Nystatin; Pregnancy; Pregnancy Complications, Infectious; Respiratory Distress Syndrome, Newborn

Topics: Amphotericin B; Candida; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Cheilitis; Female; Folliculitis; Gastrointestinal Diseases; Humans; Immunologic Deficiency Syndromes; Intertrigo; Leukoplakia, Oral; Male; Nystatin; Paronychia

Topics: Candida; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Female; Humans; Male; Nystatin; Ointments; Powders; Suppositories; Suspensions; Tablets

The anti-inflammatory and antimicrobial activities of two topical creams, one containing halcinonide, neomycin and nystatin (HNN), and the other betamethasone valerate, gentamicin, iodochlorhydroxyquin and tolnaftate (BGI), were compared in a randomized, parallel study of 154 patients (eighty-seven secondarily infected eczematous dermatoses; sixty-seven cutaneous candidiasis). Repeated clinical assessments showed that the two creams produced equivalent therapeutic responses both in patients with infected eczematous lesions and candidiasis. HNN and BGI creams eradicated the bacterial pathogens isolated prior to treatment in 80% and 76%, respectively, of the patients with eczematous dermatoses. The organism most frequently isolated in these patients was S. aureus. Local irritation prompting discontinuance of therapy occurred in just one patient receiving HNN, and two patients receiving BGI.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone Valerate; Candidiasis, Cutaneous; Clinical Trials as Topic; Clioquinol; Female; Gentamicins; Halcinonide; Humans; Male; Neomycin; Nystatin; Random Allocation; Skin Diseases, Infectious; Tolnaftate

In 5 patients (3 children, 2 adults) suffering from familial or non-familial chronic muco-cutaneous Candidosis (CMCC) combined with cellular immune deficiencies of different extent, an immunostimulating therapy regimen with levamisole was performed over 6 months. Post-treatment clinical and immunological re-examinations offered a favourable effect on the cellular immune system in all patients. As to the general health condition, in the children all clinical symptoms of CMCC clearly improved or disappeared completely, whereas in both adult patients no satisfactory clinical effect of levamisole therapy could be observed so far.

Topics: Adult; Candidiasis, Cutaneous; Chemotaxis, Leukocyte; Child; Chronic Disease; Clinical Trials as Topic; Clotrimazole; Drug Evaluation; Drug Therapy, Combination; Female; Granulocytes; Humans; Levamisole; Lymphocytes; Male; Nystatin; Phagocytosis; Tablets; Time Factors

In a multi-centre double-blind trial, 31 patients with proven bilateral candidal lesions of the flexures were treated for 14 days with nystatin cream on one side and with a combination of nystatin and triamcinolone acetonide cream on the other. Both treatments proved equally effective in terms of mycological cure and clinical improvement. There was a trend in favour of the combination preparation being preferred by both patients and physicians because of more rapid relief of symptoms.

Topics: Adolescent; Adult; Aged; Candidiasis, Cutaneous; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Infant; Male; Middle Aged; Nystatin; Triamcinolone Acetonide

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Child; Child, Preschool; Clinical Trials as Topic; Clioquinol; Dermatitis; Drug Combinations; Drug Evaluation; Female; Glucocorticoids; Humans; Hydrocortisone; Infant; Male; Middle Aged; Neomycin; Nystatin; Pregnenediones

Sixty-four patients were treated for inflammatory dermatoses or cutaneous candidiasis with a new corticosteroid combination drug, halcinonide-neomycin-nystatin (HNN). In 50 patients treated for psoriasis, atopic dermatitis, eczematous dermatitis, or neurodermatitis, HNN was evaluated in a double-blind, paired comparison study with hydrocortisone (HC) as the control drug. HNN was superior in 24 patients, HC was superior in 6, and the responses were equal in 18. The overall therapeutic response was Excellent with HNN in 29 patients as compared to 14 with HC. The anticandidal properties of HNN were assessed in a parallel study with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The most frequently treated conditions were "erosio interdigitalis blastomycotica" and candidal lesions of the neck region. The response with HNN was Excellent in 7 of 14 patients as compared to 4 out of 14 treated with I-HC.

Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Dermatitis; Drug Combinations; Drug Evaluation; Female; Humans; Hydrocortisone; Male; Neomycin; Nystatin; Pregnenediones; Triamcinolone Acetonide

In a double-blind trial clotrimazole cream was compared with tolnaftate cream in the treatment of dermatophytoses and with nystatin cream in the treatment of candidoses. Clotrimazole was shown to be effective against both dermatophytoses and candidoses and was as effective and acceptable as tolnaftate and nystatin creams in each condition.

Topics: Administration, Topical; Adolescent; Adult; Antifungal Agents; Arthrodermataceae; Candida; Candidiasis, Cutaneous; Child; Child, Preschool; Clinical Trials as Topic; Clotrimazole; Dermatomycoses; Epidermophyton; Female; Humans; Male; Microsporum; Middle Aged; Nystatin; Skin; Tinea; Tolnaftate; Trichophyton

Topics: Administration, Topical; Adult; Aged; Candida albicans; Candidiasis, Cutaneous; Cytosine; Female; Flucytosine; Humans; Male; Middle Aged; Nystatin

Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Cutaneous; Child; Clinical Trials as Topic; Female; Humans; Hydroxides; Male; Nystatin; Ointments; Phenyl Ethers; Potassium

Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Candida albicans; Candidiasis, Cutaneous; Drug Combinations; Evaluation Studies as Topic; Glucocorticoids; Humans; Neomycin; Nystatin; Skin Diseases, Infectious; Staphylococcal Infections; Triamcinolone Acetonide; Tyrothricin

Topics: Administration, Topical; Adolescent; Adult; Aged; Benzoates; Candida albicans; Candidiasis, Cutaneous; Clinical Trials as Topic; Corynebacterium; Female; Humans; Imidazoles; Malassezia; Male; Middle Aged; Nocardia Infections; Nystatin; Salicylates; Tinea; Tinea Versicolor; Trichophyton; Trityl Compounds

Topics: Candidiasis, Cutaneous; Clinical Trials as Topic; Drug Combinations; Eczema; Evaluation Studies as Topic; Humans; Hydroxamic Acids; Intertrigo; Neomycin; Nystatin; Skin Diseases

Topics: Adult; Aged; Candida; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Nystatin; Penicillin G; Rectal Diseases; Tetracycline

Topics: Amphotericin B; Candidiasis, Cutaneous; Humans; Nystatin; Paronychia

Congenital cutaneous candidiasis (CCC) is a challenging diagnosis due to various rash presentations. Inadequate early treatment is associated with high rates of dissemination and death. The effects of early diagnosis, dermatologic presentation, and antifungal treatment on outcomes are lacking.. CCC cases were reviewed from 2 academic neonatal intensive care units (NICUs) from 2004 to 2015. We defined CCC as a diffuse rash involving the body, extremities, face or scalp, and/or funisitis, presenting in the first week (≤7 days), with identification of Candida species from skin or mucous membrane cultures, and/or by culture or staining of the placenta or umbilical cord.. CCC occurred in 0.1% of all NICU admissions (21 of 19 303) and 0.6% of infants <1000 grams birth weight. Median gestational age of CCC infants was 26 3/7 (range, 23 0/7-40 4/7) weeks. Skin findings were commonly present on the day of birth [median (range): 0 (0-6) days], appearing most frequently as a desquamating, maculopapular, papulopustular, and/or erythematous diffuse rash. When systemic antifungal therapy was started empirically at the time of rash presentation and continued for a median (interquartile range) of 14 (14-15) days, all patients survived and none developed dissemination. Delaying systemic treatment, exclusive use of nystatin, and treating for <10 days was associated with Candida bloodstream dissemination.. CCC is an invasive infection that presents as a diffuse rash in preterm and term infants. Prompt systemic antifungal treatment at the time of skin presentation for ≥14 days prevents dissemination and Candida-related mortality.

Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis; Candidiasis, Cutaneous; Drug Administration Routes; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Intensive Care Units, Neonatal; Male; Medical Records; Nystatin; Pregnancy; Skin; Treatment Outcome; Young Adult

One of the most common fungal skin infections is candidosis. Topical application of drugs at the pathological sites offers potential advantage of direct drug delivery to the site of action. The main aim of this work was to evaluate an optimal nystatin nanoemulsion for topical application avoiding undesirable side effects as systemic absorption and toxicity. Surface morphology and droplet size distribution of nystatin nanoemulsion was determined by transmission electronic microscopy and dynamic light scattering. Vertical diffusion Franz-type cells and high-performance liquid chromatography were used to perform the in vitro release and ex vivo human skin permeation studies. Transdermal permeation parameters were estimated from the permeation values using different theoretical approaches. Microbiological studies were performed to evaluate the antifungal effect. Nanoemulsion exhibited a spherical shape with smooth surface and mean droplet size between 70 and 80 nm. The pharmacokinetic release showed the nanoemulsion is faster than commercial ointment Mycostatin(®) improving the potential therapeutic index. Permeation studies demonstrated nystatin was not absorbed into systemic circulation and the retained amount in the skin was sufficient to ensure an antifungal effect. This antifungal effect was higher for nystatin loaded nanoemulsion than nystatin itself. A therapeutic improvement of the nystatin nanoemulsion treatment compared with the classical ones was achieved.

Topics: Antifungal Agents; Candidiasis, Cutaneous; Drug Stability; Emulsions; Humans; Microbial Sensitivity Tests; Nanoparticles; Nystatin; Particle Size; Permeability; Skin

Topics: Animals; Anti-Infective Agents, Local; Antifungal Agents; Axilla; Biopsy, Needle; Camelids, New World; Candida albicans; Candidiasis, Cutaneous; Chlorhexidine; Female; Male; Nystatin; Ointments; Skin

Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Female; Humans; Infant, Newborn; Male; Nystatin; Pregnancy; Pregnancy Complications, Infectious; Vulvovaginitis

Acarbose and nystatin are usually well-tolerated drugs because of their minimal intestinal absorption. We report herein two cases of acute generalized exanthematous pustulosis induced by these two molecules.. A 43 year-old man with a history of insulin-deficient diabetes was admitted to our department for a febrile generalized cutaneous pustular erythema, that had appeared 48 hours after acarbose (Glucor) introduction. Acarbose was discontinued and the eruption resolved in one week. A 29 year-old man developed a flexural erythema twenty four hours after nystatin (Mycostatin) treatment, progressing towards a febrile pustular erythroderma, with elevated neutrophilic and eosinophilic counts. The lesions regressed rapidly with topical steroid treatment. The patch tests performed a few months later with Mycostatin and nystatin were positive.. The clinical presentation of these two patients was typical of acute generalized exanthematous pustulosis, according to the EuroSCAR group criteria and acarbose and nystatin were the most likely factors that caused the disease according to the French unexpected or toxic drug reaction assessment. The minimal intestinal absorption of these two molecules explains their usual good tolerance. However, some cases of toxiderma have already been reported. There is the first described case of acute generalized exanthematous pustulosis with acarbose. Our two observations underline the possibility of severe toxiderma induced by low-absorbed and low-blood concentration molecules and focus on the need to take them in account in the toxiderma anamnesis.

Topics: Acarbose; Adult; Antifungal Agents; Candidiasis, Cutaneous; Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug Eruptions; Genital Diseases, Male; Humans; Hypoglycemic Agents; Intestinal Absorption; Male; Nystatin; Patch Tests; Skin Diseases, Vesiculobullous

In the period between December 1992 and September 1993 a total of 1060 clinically suspected cases of dermatomycoses were examined for causative fungi. Of these 330 (31%) were suspected as cutaneous candidosis. A higher incidence was observed in adults (62.9%) than in children (36.2%) and infants (19.5%). The infected patients that were adults were divided into four categories: diabetics; those receiving steroid; those receiving antibiotic therapy; and a non-risk control group. Analysis of the data revealed that the incidence rate appears to be approximately doubled in diabetes (49.3%), steroid therapy (33.8%) and antibiotic therapy (27.4%) than in the control group (15.7%). Candida albicans was the most frequent isolate (57.6%) followed by Candida tropicalis (16.5%).

Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Child; Child, Preschool; Female; Humans; Incidence; Infant; Jordan; Male; Middle Aged; Nystatin

Topics: Candida; Candidiasis, Cutaneous; Diagnosis, Differential; Feces; Humans; Intestines; Nystatin; Skin Diseases

Topics: Candida albicans; Candidiasis, Cutaneous; Cerebrospinal Fluid; Female; Humans; Infant, Newborn; Meningitis, Fungal; Nystatin

Congenital candida infection is a rare disease, although the incidence of candida vaginitis during pregnancy is high. We report on five cases each showing patterns considered typical for candida infection. The infective agent can cause chorioamnionitis even in the presence of intact fetal membranes. An intrauterine device (IUD) has been proved to be a risk factor for a congenital candida infection. The pathogenetic significance of contamination with candida for the fetus appears to depend largely on gestational age. A premature infant with a birth-weight less than 1500 g presented with bilateral candida endophthalmitis which was cured by intravenous Fluconazole therapy. Another premature infant weighing 800 g at birth developed a systemic candida infection. The other three more mature infants had milder symptoms, two of them presented with cutaneous candidiasis.

Topics: Adult; Amniocentesis; Amphotericin B; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Chorioamnionitis; Drug Therapy, Combination; Endophthalmitis; Female; Fetal Membranes, Premature Rupture; Flucytosine; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Nystatin; Pregnancy

The results are presented of in vitro investigations of the sensitivity of 225 strains of yeast-like fungi to nystatin. The strains were isolated from cutaneous and mucosal lesions. In the study nystatin concentration 10 micrograms/ml of the substrate was used and a two-grade scale of evaluation was applied: sensitive or resistant to the drug. It was found that 56.7% of the tested strains were resistant to this nystatin concentration. The obtained data were compared with those obtained in 1972 when all the tested strains were sensitive to nystatin in this concentration. The study showed that the resistance to nystatin has been rising in these organisms with years.

Topics: Candida; Candida albicans; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Culture Media; Drug Resistance, Microbial; Female; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Nystatin

The concentrations of nystatin excreted with faeces during and after oral application of 3 x 150,000 IU/d, either continuously for 14-21 days or every second day were determined in 42 newborns at risk by means of a bioassay (agar diffusion test). Results indicate that nystatin is distributed heterogeneously in the gastrointestinal tract. The excretion occurs discontinuously. 24 to 48 h after beginning of therapy there were effective concentrations of nystatin in the faeces. The daily application of 3 x 150,000 IU nystatin is recommended.

Topics: Biological Availability; Candidiasis, Cutaneous; Candidiasis, Oral; Diaper Rash; Dose-Response Relationship, Drug; Drug Administration Schedule; Feces; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Nystatin; Risk Factors

Cutaneous candidiasis is a common fungal infection that can affect intertriginous or occluded areas, mucous membranes, the glabrous skin, and the nails. The diagnosis is confirmed by microscopic examination of a potassium hydroxide preparation, by Gram's stain or Polysciences Multiple Stain, or by culture when appropriate. Safe, simple, and effective treatment is available. Physical measures that promote dryness are helpful.

Topics: Administration, Cutaneous; Administration, Oral; Candida; Candidiasis, Cutaneous; Humans; Ketoconazole; Nail Diseases; Nystatin; Physicians, Family; Skin

This article describes the in vivo evaluation of a new topical preparation (Zincostatin) indicated for Candida albicans infected diaper rash. In order to study the influence of the 20% zinc oxide (W/W) (a protectant) on the anti-candidal efficacy of the 100,000 U/g of nystatin found in the ointment, groups of guinea pigs received different treatments with or without local occlusion. Zinc oxide, nystatin, or the combination of both were applied, in the ointment base, on the backs of the animals inoculated with a fresh strain of Candida albicans. Macroscopic and microbiological evaluation of the skin lesions were assessed at regular intervals during 21 days. While the two treatments containing nystatin were more effective than zinc oxide alone, the latter agent did not decrease the efficacy of the antifungal drug in combination therapy. Also, zinc oxide seemed to afford some protection against local maceration induced by occlusion, which increased the severity of the infection.

Topics: Animals; Candidiasis, Cutaneous; Colony Count, Microbial; Drug Therapy, Combination; Guinea Pigs; Humans; Male; Nystatin; Zinc; Zinc Oxide

Topics: Adult; Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Female; Humans; Infant, Newborn; Male; Nystatin; Pregnancy; Pregnancy Complications, Infectious

Candidal granuloma in an infant of 11 months is described. The disease has developed at the age of 3.5 months after administration of ampicillin for an acute respiratory viral disease and otitis. The diagnosis has been confirmed by microscopic examinations and cultivation. The condition has been cured by oral nystatin and external batrafen cream.

Topics: Administration, Oral; Candidiasis, Cutaneous; Ciclopirox; Drug Therapy, Combination; Female; Humans; Infant; Nystatin; Ointments; Pyridones; Scalp Dermatoses

Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis, Cutaneous; Child; Ciclopirox; Clotrimazole; Econazole; Female; Humans; Imidazoles; Male; Miconazole; Middle Aged; Nystatin; Pyridones

Topics: Adult; Aged; Candidiasis, Cutaneous; Child; Child, Preschool; Dermatologic Agents; Drug Evaluation; Drug Tolerance; Female; Humans; Infant; Male; Middle Aged; Nystatin; Ointments; Triamcinolone Acetonide

Topics: Candida; Candidiasis; Candidiasis, Cutaneous; Feces; Humans; Intestinal Diseases; Microbial Sensitivity Tests; Nystatin

Twenty-five infants and children with Candida infections in the perianal, genital and inguinal areas and on the skin normally covered by the napkin or diaper, confirmed by culture tests and microscopy, were treated with a new combined foam preparation containing the active substances nystatin, chlorhexidine and prednisolone. Even partially very severe lesions with multiple, satellitelike colonies on the trunk, extremities and neck were, without exception, cured within a maximum of 13 days. After disappearing of the exudative stage, intermittent treatment with a rather more greasy excipient (Excipial Cream) containing no active substance, has proved beneficial.

Topics: Administration, Topical; Candidiasis, Cutaneous; Child; Child, Preschool; Chlorhexidine; Diaper Rash; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Male; Nystatin; Prednisolone

Topics: Amphotericin B; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Esophagitis; Female; Humans; Ketoconazole; Leukemia, Lymphoid; Male; Nystatin; Thrombocytopenia

Topics: Candidiasis, Cutaneous; Candidiasis, Oral; Dermatomycoses; Diagnosis, Differential; Griseofulvin; Humans; Nystatin; Tinea

Topics: Amphotericin B; Candidiasis, Cutaneous; Chloramphenicol; Drug Therapy, Combination; Folliculitis; Griseofulvin; Humans; Male; Middle Aged; Nystatin

Topics: Candida albicans; Candidiasis, Cutaneous; Candidiasis, Oral; Enteritis; Feces; Humans; Infant; Nystatin

The authors present a review of the epidemiology, pathology, diagnosis and treatment of candidiasis in the child. Their studies on the favoring factors in cutaneous forms as well as their experiences in pulmonary forms are emphasized.

Topics: Amphotericin B; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Child; Clotrimazole; Complement C5; Female; Flucytosine; Humans; Immunity, Cellular; Immunologic Deficiency Syndromes; Miconazole; Nystatin

Topics: Adult; Breast Diseases; Candidiasis, Cutaneous; Dermatomycoses; Female; Humans; Nystatin

Topics: Age Factors; Antifungal Agents; Candidiasis, Cutaneous; Dermatitis, Seborrheic; Humans; Infant; Nystatin

Three newborn infants are described in whom a generalized maculopapular rash was observed at birth or soon after. The eruption rapidly became vesicular, and in one infant it became bullous, and was followed in each case by extensive desquamation. Candida albicans was demonstrated on direct smear and on culture from the skin vesicles, and evidence of an intrauterine infection with this organism was detected on histologic examination of the placenta in at least two of the cases. Agglutinating antibodies to Candida were present in the sera of all three infants, though these may have reflected transplacental passage of maternal antibody.

Topics: Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Female; Humans; Infant, Newborn; Male; Nystatin; Placenta; Pregnancy; Pregnancy Complications, Infectious

In a 20-month period, generalized chronic cutaneous candidiasis developed in 3 performing bottle-nosed dolphins kept in an indoor pool. Extensive esophagogastric ulcerations were observed in 2 of the dolphins, each of which died, presumably because of these lesions. The 3rd dolphin died during a surgical procedure and did not have any esophagogastric ulcerations. Candida albicans was the only organism isolated from skin lesions but was not isolated from adjacent normal skin of dolphins. Treatment with antifungal drugs was unsuccessful. Subsequently, immunopotentiating treatment with levamisole phosphate resulted in formation of granulation tissue and healing of the skin lesions.

Topics: Animals; Animals, Zoo; Candidiasis, Cutaneous; Dolphins; Esophageal Diseases; Esophagus; Female; Levamisole; Male; Nystatin; Skin; Stomach; Stomach Ulcer; Ulcer

Topics: Age Factors; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Mouth Diseases; Nystatin; Rectum; Skin

Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Female; Flucytosine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunologic Deficiency Syndromes; Immunotherapy; Lymphocyte Activation; Microbial Sensitivity Tests; Nystatin; Skin Diseases; Staphylococcal Infections

Two cases of congenital cutaneous candidiasis are presented in order to call attention to this rarely recognized and infrequently reported condition. Clinical features and appropriate cultures are useful in differentiating the lesions from other more common dermatoses of the neonatal period. Microscopic examination of the placenta may disclose fungal funisitis or chorioamnionitis, thus defining the congenital nature of the disease. Topical antifungal therapy is sufficient unless systemic candidiasis is present. No evidence of impaired immunological responsiveness was found in the two infants.

Topics: Candidiasis, Cutaneous; Diagnosis, Differential; Female; Humans; Immunoglobulin M; Infant, Newborn; Male; Nystatin

Topics: Amphotericin B; Antifungal Agents; Balanitis; Candida albicans; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Coloring Agents; Contraceptives, Oral; Diabetes Complications; Female; Humans; Infant, Newborn; Male; Nails; Nystatin; Paronychia; Pregnancy; Pregnancy Complications, Infectious; Saccharomyces

Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis, Cutaneous; Carbonates; Gentian Violet; Hexachlorophene; Hydrocarbons, Halogenated; Imidazoles; Natamycin; Neomycin; Nystatin; Quinolines; Rabbits; Tolnaftate

Topics: Candidiasis, Cutaneous; Electrophoresis; Hand Dermatoses; Humans; Nystatin; Solutions

Topics: Amphotericin B; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Contraceptive Agents; Female; Granuloma; Humans; Infant, Newborn; Infant, Newborn, Diseases; Natamycin; Nystatin; Pregnancy

Topics: Amphotericin B; Candida albicans; Candidiasis, Cutaneous; Cell Migration Inhibition; Child; Female; Histoplasmin; Humans; Hypersensitivity, Delayed; Immunity, Maternally-Acquired; Immunization, Passive; Leukocytes; Lymphocyte Activation; Nystatin; Skin Tests

Topics: Aged; Amphotericin B; Antigens; Candidiasis, Cutaneous; Chronic Disease; Cobalt Isotopes; Female; Humans; Immunity, Cellular; Lectins; Lymphocytes; Mediastinal Neoplasms; Nystatin; Skin Tests; Thymoma

Topics: Candidiasis, Cutaneous; Diagnosis, Differential; Diaper Rash; Humans; Infant; Infant, Newborn; Nystatin

Topics: Acrodermatitis; Adult; Candidiasis, Cutaneous; Chronic Disease; Humans; Hypersensitivity; Male; Middle Aged; Nystatin

Topics: Candidiasis, Cutaneous; Candidiasis, Oral; Child; Female; Fingers; Granuloma; Humans; Nystatin; Scalp Dermatoses

Topics: Candida; Candidiasis, Cutaneous; Culture Media; Diffusion; Drug Resistance, Microbial; Drug Storage; Humans; Microbial Sensitivity Tests; Nystatin; Ointments; Refrigeration

Topics: Balanitis; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Female; Humans; Male; Natamycin; Nystatin; Ointments; Paronychia; Powders; Quinolines; Suspensions

Topics: Antifungal Agents; Candidiasis, Cutaneous; Chlorphenesin; Dermatomycoses; Griseofulvin; Humans; Nystatin; Pyrrolidinones; Undecylenic Acids

Topics: Addison Disease; Adolescent; Candida; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Female; Humans; Nystatin

Topics: Candidiasis, Cutaneous; Diagnosis, Differential; Humans; Nails; Nystatin; Onychomycosis; Paronychia; Pseudomonas Infections; Psoriasis; Staphylococcal Infections; Streptococcal Infections

Topics: Candidiasis, Cutaneous; Child, Preschool; Dermatitis, Seborrheic; Diaper Rash; Eczema; Female; Humans; Nystatin; Ointments; Psoriasis; Terminology as Topic

Topics: Adolescent; Amphotericin B; Candidiasis, Cutaneous; Candidiasis, Oral; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Middle Aged; Nystatin; Oral Manifestations; Sarcoidosis

Topics: Adult; Amphotericin B; Antifungal Agents; Candidiasis, Cutaneous; Dermabrasion; Dermatologic Agents; Humans; Male; Nystatin

Topics: Adult; Candida; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Female; Humans; Infant, Newborn; Nystatin; Placenta; Pregnancy; Pregnancy Complications, Infectious

Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis, Cutaneous; Chloroquinolinols; Gentian Violet; Nystatin; Ointments; Pyridines; Rabbits; Tin

Topics: Candidiasis, Cutaneous; Female; Humans; Middle Aged; Nystatin

Topics: Balanitis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Dermatitis; Diabetes Complications; Drug Hypersensitivity; Female; Humans; Infant; Male; Middle Aged; Neomycin; Nystatin; Pregnancy; Pregnancy Complications, Infectious

Topics: Antifungal Agents; Candidiasis, Cutaneous; Drug Therapy; Griseofulvin; Humans; Nystatin; Tinea Versicolor; Toxicology

Topics: Bacteriological Techniques; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Dermatitis, Exfoliative; Diagnosis, Differential; Drug Eruptions; Female; Fetal Diseases; Fludrocortisone; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Neomycin; Nystatin; Paronychia; Pathology; Pregnancy; Pregnancy Complications, Infectious

Topics: Bacitracin; Candidiasis, Cutaneous; Focal Infection; Humans; Irritants; Neomycin; Nystatin; Paronychia; Pathology; Polymyxins; Triamcinolone Acetonide

Topics: Candidiasis; Candidiasis, Cutaneous; Female; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Nystatin; Pregnancy

Topics: Adolescent; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis, Cutaneous; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Eyelids; Humans; Nystatin; Skin Ulcer

Topics: Candida albicans; Candidiasis; Candidiasis, Cutaneous; Cheilitis; Humans; Nystatin; Triamcinolone

Topics: Amphotericin B; Candida; Candida albicans; Candidiasis; Candidiasis, Cutaneous; Desensitization, Immunologic; Gentian Violet; Humans; Hypersensitivity; Nystatin

Topics: Achondroplasia; Amphotericin B; Bronchiectasis; Candidiasis, Chronic Mucocutaneous; Candidiasis, Cutaneous; Child; Granuloma; Humans; Injections, Intravenous; Nystatin; Organic Chemicals; Pathology

Topics: Addison Disease; Administration, Cutaneous; Adrenal Insufficiency; Amphotericin B; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Gentian Violet; Humans; Hypoadrenocorticism, Familial; Hypoparathyroidism; Nystatin; Sweden

Topics: Candidiasis; Candidiasis, Cutaneous; Diagnosis; Humans; Nystatin

Topics: Administration, Cutaneous; Adolescent; Amphotericin B; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Child; Female; Humans; Infant; Infant, Newborn; Nystatin

Topics: Administration, Cutaneous; Candidiasis, Cutaneous; Candidiasis, Oral; Chloroquine; Facial Paralysis; Hair; Hair Follicle; Humans; Melkersson-Rosenthal Syndrome; Nystatin

Topics: Amphotericin B; Antifungal Agents; Candidiasis; Candidiasis, Cutaneous; Nystatin; Skin Diseases

Topics: Candidiasis; Candidiasis, Cutaneous; Disease Management; Humans; Nystatin; Skin Diseases

Topics: Anti-Bacterial Agents; Candidiasis; Candidiasis, Cutaneous; North Carolina; Nystatin; Skin Diseases

Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibiotics, Antitubercular; Candidiasis; Candidiasis, Cutaneous; Cardiovascular Agents; Dermatologic Agents; Nystatin; Skin Diseases